Project Grant R44AI188623
Award Date
12/17/24
Completion Date
11/30/26
Dollars Obligated
$1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92122, USA
Similar Awards
This $1,670,110 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel, multi-compartment intravaginal ring (IVR) for the prevention of genital herpes (HSV) and unintended pregnancy. The key products and services funded under this award include: Evaluating a panel of small-molecule inhibitors of soluble adenylyl cyclase (SAC) to select a lead...
This $1,025,000 project grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting the development of MM-009, a sustained-release intravaginal ring that continuously delivers lactic acid to prevent and treat bacterial vaginosis. The awardee, Mucommune LLC, a biopharmaceutical company in Durham, North Carolina, is focused on advancing this novel vaginal drug delivery technology. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $216,736 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to study the role of DNA-PKcs in regulating R-loops during human papillomavirus (HPV) replication. The research aims to uncover how DNA-PKcs activation is necessary to maintain R-loop homeostasis in HPV-positive cells, as well as examine the impact of DNA-PKcs inhibition on the HPV lifecycle. Through...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $426,648 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Dartmouth-Hitchcock Clinic. The grant, titled "ADVANCING ANTIMICROBIAL PHOTODYNAMIC THERAPY TO PREVENT INFECTION IN OSSEOINTEGRATED PROSTHESIS PATIENTS," will fund research to develop antimicrobial photodynamic therapy for preventing infections in patients with osseointegrated prosthetic implants. As part of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $208,575 to develop an ionic liquid-based nanoemulsion containing a combination of antiretroviral drugs for the oral and transdermal treatment of HIV infection. The goal is to improve the oral bioavailability and skin permeability of the integrase inhibitor dolutegravir and the non-nucleoside reverse...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,564,570 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on identifying drivers of genital inflammation and HIV acquisition in women living in sub-Saharan Africa. The project will run from August 2024 through June 2029. The grant supports several key products and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing a potentially curative gene editing therapy for latent Herpes Simplex Virus Type 2 (HSV-2) infection. The $303,731 award to Caladan Therapeutics, Inc. aims to select and validate a lead meganuclease variant that can specifically target and eliminate HSV-2 from latently infected ganglionic neurons, which...
This $1,000,000 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Phagepro, P.b.c., a minority-owned, woman-owned small business. The grant supports the development of a prophylactic cholera phage cocktail, with a project period from December 16, 2024, to May 31, 2027. This work aims to create targeted phage interventions that can potentially reduce cholera infection rates and...